Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab
A phase 3 trial of Datopotamab deruxtecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Daiichi Sankyo, active and no longer recruiting.
Overview
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT05215340 by Daiichi Sankyo, with 740 participants enrolled, started 2022-03-04 and due to reach its primary completion in 2030-03-04. Interventions recorded: Datopotamab Deruxtecan, Pembrolizumab. Conditions listed: Metastatic Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Datopotamab deruxtecan, Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer.
- TrialStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Shares Daiichi Sankyo, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Datopotamab deruxtecan, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Shares Datopotamab deruxtecan, Daiichi Sankyo, Non-small-cell lung cancer.
- TrialHERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Shares Daiichi Sankyo, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.